Basic Information

Gene symbol S Synonyms E2 Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas
Description spike glycoprotein

GTO ID GTC2924
Trial ID NCT05228730
Disease COVID-19
Altered gene S
Therapeutic/Target gene Therapeutic gene
TherapymRNA vaccine
Treatment BNT162b2|COMIRNATY|Tozinameran;mRNA-1273|Elasomeran|Spikevax
Location approved UK, Bahrain, Israel, Canada, US, Rwanda, Serbia, United Arab Emirates, China, Mexico, Kuwait, Singapore, Saudi Arabia, Chile, Switzerland, EU, Ghana, Colombia, Philippines, Indonesia, Australia, Peru, South Korea, New Zealand, Japan, Brazil, Sri Lanka, Vietnam, South Africa, Thailand, Oman, Egypt, Malaysia;UK, Canada, China, Switzerland, Japan, EU, Australia, South Korea, Singapore, US
PhasePhase3
Recruitment statusCompleted
TitleA Randomised Controlled Trial to Assess the Immunogenicity, Safety, and Reactogenicity of Standard-dose Versus Fractional Doses of COVID-19 Vaccines (Pfizer-BioNTech or Moderna) Given as an Additional Dose After Priming With Pfizer-BioNTech or AstraZeneca in Healthy Adults in Australia-MIACoV
Year2022
CountryAustralia
Company sponsorMurdoch Childrens Research Institute
Other ID(s)81764
Vector information
Vectorlipid nanoparticle

Clinical Result

Cohort1: Tozinameran_dose level 1
Administration route None
Dosage Tozinameran, standard dose, on day 0
Age Adult, Older_Adult
Cohort2: Tozinameran_dose level 2
Administration route None
Dosage Tozinameran, 15 mcg, on day 0
Age Adult, Older_Adult
Cohort3: Elasomeran_dose level 4
Administration route None
Dosage Elasomeran, 50 mcg, on day 0
Age Adult, Older_Adult
Cohort4: Elasomeran_dose level 3
Administration route None
Dosage Elasomeran, 20 mcg, on day 0
Age Adult, Older_Adult

Relationship Graph

Overview of Knowledge Graph